Skip to main content

Table 1 HLA associations with adverse drug reactions

From: Pharmacogenomics of adverse drug reactions

Type of toxicity Drug HLA allele Type of study Approximate odds ratio Reference(s)
Hypersensitivity Abacavir B*57:01 Candidate gene 800 [25, 26]
Liver injury Amoxicillin-clavulanate DRB1*15:01-DQB1*06:02 A*02:01 Candidate gene and GWA 3 2.3 [14, 15, 72, 93, 94]
  Ximelagatran DRB1*07:01-DQA1*02:01 GWA Not available (P = 6.0 × 10-6) [95]
  Ticlopidine A*33:03 Candidate gene 13 [96]
  Flucloxacillin B*57:01 GWA 80 [17]
  Lumiracoxib DRB1*15:01-DQB1*06:02 GWA 5.3 [97]
  Lapatinib DQA1*02:01 GWA and candidate gene 9 [98]
  Nevirapine DRB1*01 Candidate gene 3 [35, 99]
SJS and TEN Carbamazepine B*15:02 Candidate gene 895 [21]
Various skin reactions, including SJS and TEN Carbamezepine A*31:01 GWA 12 [23, 24]
Various skin reactions including SJS and TEN Allopurinol B*58:01 Candidate gene 400 [29]
Various skin reactions Nevirapine B*35:05
Cw*8
Cw*04
Candidate gene and GWA 30
15
2.5
[33, 34]
[31, 32]
[35]
  1. GWA, genome-wide association; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis.